At a glance
ClinicalIndex Comparison RecordN/ACompleted· 568 enrolled
Drug / intervention
ReMMi-D Digital Therapeuticdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Double-blind, Parallel-Group, Virtual Study to Evaluate the Effectiveness and Safety of Two Digital Therapeutics in Late Adolescents and Adults for the Prevention of Episodic Migraine
In Brief
A clinical study evaluating ReMMi-D Digital Therapeutic for Migraine and 3 related conditions. Completed, enrolled 568 participants across 1 site.
Detailed Summary
Randomized study of two digital therapeutics for the prevention of episodic migraine
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine, Episodic Migraine, Headache, Headache, Migraine
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
202420252026
Enrollment StartMar 2023
First PostedMay 2023
Primary CompletionMay 2024
TodayJul 2026
First PostedMay 11, 2023
Enrollment StartMar 28, 2023
Primary CompletionMay 7, 2024
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 3.1 years ago
Interventions
ReMMi-D Digital Therapeuticdevice
Evaluate the effectiveness and safety of prescription mobile applications that provide an interactive, software-based intervention for the preventative treatment of episodic migraine in late adults and adolescents.